These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12088684)

  • 21. Therapeutic immunization strategies for the control of HIV-1.
    Dorrell L
    Expert Rev Vaccines; 2005 Aug; 4(4):513-20. PubMed ID: 16117708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic vaccination for chronic infectious diseases: lessons from HIV-1.
    Verrier B
    J Clin Virol; 2005 Dec; 34 Suppl 1():S9-S12. PubMed ID: 16461232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No vaccine against HIV yet--are we not perfectly equipped?
    Singh M
    Virol J; 2006 Aug; 3():60. PubMed ID: 16939652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Control of HIV-1 Pathogenesis in Viremic Nonprogressors Is Independent of Gag-Specific Cytotoxic T Lymphocyte Responses.
    Salgado M; Garcia-Minambres A; Dalmau J; Jiménez-Moyano E; Viciana P; Alejos B; Clotet B; Prado JG; Martinez-Picado J
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preventing AIDS but not HIV-1 infection with a DNA vaccine.
    Shen X; Siliciano RF
    Science; 2000 Oct; 290(5491):463-5. PubMed ID: 11183769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV T-Cell Vaccines.
    Mothe B; Brander C
    Adv Exp Med Biol; 2018; 1075():31-51. PubMed ID: 30030788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted Immune Interventions for an HIV-1 Cure.
    Perreau M; Banga R; Pantaleo G
    Trends Mol Med; 2017 Oct; 23(10):945-961. PubMed ID: 28890135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Status and current strategies of HIV vaccine development].
    Wild J; Wagner R
    Internist (Berl); 2003 Jun; 44(6):711-8. PubMed ID: 14567107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of prophylactic AIDS vaccines: the current state of affairs.
    Hanke T
    Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A strategy for prophylactic vaccination against HIV.
    Salk J; Bretscher PA; Salk PL; Clerici M; Shearer GM
    Science; 1993 May; 260(5112):1270-2. PubMed ID: 8098553
    [No Abstract]   [Full Text] [Related]  

  • 31. Aiming for successful vaccine-induced HIV-1-specific cytotoxic T lymphocytes.
    Yang OO
    AIDS; 2008 Jan; 22(3):325-31. PubMed ID: 18195558
    [No Abstract]   [Full Text] [Related]  

  • 32. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.
    Calarota SA; Kjerrström A; Islam KB; Wahren B
    Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can immune systems be trained to fight HIV?
    Balter M
    Science; 1999 Nov; 286(5444):1470-11. PubMed ID: 10610544
    [No Abstract]   [Full Text] [Related]  

  • 34. Vaccines and vaccine strategies against HIV.
    Stratov I; DeRose R; Purcell DF; Kent SJ
    Curr Drug Targets; 2004 Jan; 5(1):71-88. PubMed ID: 14738219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune correlates of HIV control.
    Prado JG; Carrillo J; Blanco-Heredia J; Brander C
    Curr Med Chem; 2011; 18(26):3963-70. PubMed ID: 21824095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy and therapeutic vaccines in HIV infection.
    García F; Ruiz L; López-Bernaldo de Quirós JC; Moreno S; Domingo P
    Enferm Infecc Microbiol Clin; 2005 Jul; 23 Suppl 2():84-104. PubMed ID: 16373008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A boost for the immune system.
    TreatmentUpdate; 1998 Nov; 10(9):3-4. PubMed ID: 11365925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progress towards an AIDS mucosal vaccine: an overview.
    Yuki Y; Nochi T; Kiyono H
    Tuberculosis (Edinb); 2007 Aug; 87 Suppl 1():S35-44. PubMed ID: 17652028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rethinking globally relevant vaccine strategies to human immunodeficiency virus type-1.
    Gray CM; Puren AJ
    Arch Immunol Ther Exp (Warsz); 2000; 48(4):235-41. PubMed ID: 11059639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-HIV adaptive immunity: determinants for viral persistence.
    Yamamoto H; Matano T
    Rev Med Virol; 2008; 18(5):293-303. PubMed ID: 18416450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.